New Two-Step therapy aims to stop chronic kidney transplant rejection
NCT ID NCT07718308
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests a new treatment for chronic active antibody-mediated rejection (caABMR) in kidney transplant recipients. Patients receive a single injection of a CD38 monoclonal antibody to deplete harmful immune cells, followed by long-term azathioprine pills to maintain control. The goal is to slow or stop the decline in kidney function. Twenty participants across six centers in China will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a CD38 monoclonal antibody (single injection) followed by azathioprine pills
- What this could lead to
- If successful, this approach could offer a new way to treat chronic rejection in kidney transplant patients, potentially preserving kidney function longer without needing stronger lifelong immune suppression.
- What could go wrong
- This is a small, early exploratory study with only 20 participants, so results may not apply broadly. The treatment carries risks from immune suppression, including infection and possible side effects from the antibody.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY MEDIATED REJECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- Gene expression platform could revolutionize kidney transplant rejection diagnosis
- Smartphone app and booklet could help kidney transplant patients stick to medications
- Could less heart screening be safer for kidney transplant patients?
- Could removing a catheter sooner after kidney transplant cut infection risk?